Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kansas for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kansas only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kansas (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Dennis Moore (NPI 1043272305)

Field	Value
Entity Type	Individual
Organization	Dennis Moore
Address	818 N Emporia St
City	Wichita
State	KS
ZIP	67214
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	April 3, 2006

Payer Source	Total Paid
Medicare	$6.7M
Medicaid	$0

Key Findings

This provider’s Medicare business is heavily concentrated in high-cost oncology injectables and immunotherapies: J9271 (pembrolizumab) alone accounts for $1.5M and 24.7% of the provider’s total Medicare revenue, and the precomputed top 3 codes together account for 43.7% of total Medicare revenue. The itemized CPT/HCPCS mix (multiple immune checkpoint inhibitors and monoclonal antibodies) indicates an infusion-centered hematology/oncology practice that earns the bulk of its revenue from drug administration rather than ancillary procedures or broad outpatient primary care services.

The practice is effectively single-payer from a government perspective: total Medicare revenue is $6.7M while there is no Medicaid billing on file, so payer mix is dominated by Medicare with no Medicaid footprint recorded. That single-payer concentration should be treated as a core operational risk and strategic reality for any analyses of reimbursement sensitivity or patient panel composition.

On several high-cost drugs the provider ranks well above peers nationally, signaling regional or specialized scale in specific therapies: J9271 ranks #52 of 1841 providers nationally (97th percentile; notably above typical national volume for this code), J2796 ranks #3 of 20 providers nationally (89th percentile), and J0897 ranks in the 95th percentile nationally (notably above typical national volume). These placements suggest market leadership on selected oncology biologics and supportive agents rather than broad dominance across all oncology codes.

Other oncology administration metrics point to a high-volume infusion practice beyond drug revenue: 96413 (chemotherapy administration) is reported as an extreme outlier nationally (ranks #29 of 7514 providers; 100th percentile) and 99214 (established patient office visits) is also an extreme outlier (ranks #2362 of 479517 providers; 100th percentile). Together these high ranks imply a large throughput of outpatient oncology encounters and chemotherapy sessions relative to national peers.

Not all high-revenue codes are outliers — several commonly used oncology products show typical, unremarkable national volumes for this provider. Examples include J9145 (daratumumab) at $736.3K and J9299 (nivolumab) at $456.5K, both described as typical volumes by their rank/percentile, which suggests the provider’s elevated overall revenue is driven by a subset of very high-volume codes rather than uniformly high volume across the entire therapeutic portfolio.

Procedure and supportive-care mix is broad and consistent with a full-service oncology clinic: the top-25 list includes imaging (78815 PET/CT), growth factors and supportive injectables (J1627, Q5108, J1449), and immune globulin (J1568). These codes indicate the practice bills for both therapeutic infusions and the supportive services that accompany oncology care, reinforcing an operational model centered on outpatient infusion and imaging workflows.

Several codes register as unusually frequent claims counts with low per-claim reimbursement, indicating possible pass-through or high-utilization supportive items: J0185 (aprepitant) shows 34.3K claims and is labeled an extreme outlier (98th percentile), and J1439 (ferric carboxymaltose) shows 30K claims (typical volume). High claim counts on low-dollar supportive drugs point to standardized supportive regimens administered at scale in infusion settings.

Tenure data show the provider’s NPI was enumerated on 2006-04-03 (~20 years ago), indicating long-standing participation in Medicare. This length of enrollment combined with consistently high percentiles on several codes supports a profile of an established hematology/oncology clinician with stable Medicare referral and treatment patterns over time.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

118 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,000	$40	$1.5M
J9145	Injection, daratumumab, 10 mg	15,340	$50	$736.3K
J9299	Injection, nivolumab, 1 mg	19,020	$20	$456.5K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	10,620	$40	$414.2K
J2796	Injection, romiplostim, 10 micrograms	5,530	$70	$397.9K
J1930	Injection, lanreotide, 1 mg	9,240	$40	$397.3K
J9173	Injection, durvalumab, 10 mg	5,320	$60	$329.7K
J0897	Injection, denosumab, 1 mg	15,300	$20	$290.7K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	6,070	$30	$206.4K
J9022	Injection, atezolizumab, 10 mg	3,170	$70	$205.9K

Showing 1–10 of 118

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 118 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kansas Distribution

Dennis Moore — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kansas

Full comparison — all codes billed, vs. state median

118 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	20	28,900	$40	$1.1M
J9299	11	10	24,550	$20	$637.2K
J1930	3	10	9,180	$40	$402.7K
J9145	3	10	6,660	$50	$394.7K
J9022	5	10	3,910	$60	$301.1K
J9144	1	10	6,300	$40	$257.2K
J9173	1	10	3,480	$60	$230.3K
J2796	1	10	2,380	$70	$208.4K
J9312	9	10	2,500	$60	$194.7K
J9301	1	10	2,910	$50	$156.8K

Showing 1–10 of 118

Related Providers

Other providers that share a Tax Identification Number (TIN) with Dennis Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bassam Mattar	KS	Hematology & Oncology Physician	$7.2M	$0
Pavan Reddy	KS	Hematology & Oncology Physician	$6.7M	$0
Jeremy Deutsch	KS	Hematology & Oncology Physician	$5.7M	$0
Travis Koeneke	KS	Hematology & Oncology Physician	$4.4M	$0
Christopher Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Shaker Dakhil	KS	Hematology & Oncology Physician	$4.4M	$0
Nassim Nabbout	KS	Hematology & Oncology Physician	$4.2M	$0
Phu Truong	KS	Hematology & Oncology Physician	$4.1M	$0
Quoc Truong	KS	Hematology & Oncology Physician	$3.9M	$0
Joseph Moore	KS	Hematology & Oncology Physician	$3.6M	$0

Nearby Providers

Other providers in the same ZIP code as Dennis Moore, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Craig Resources LLC	KS	Home Health Agency	$0	$97.3M
Paradigm Services Inc	KS	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$42.4M
Wesley Medical Center LLC	KS	General Acute Care Hospital	$0	$30.2M
Gracemed Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$18.3M
Healthcore Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$15.3M
Diversified Family Services LLC	KS	Home Health Agency	$0	$13.9M
Alpha Service	KS	Developmentally Disabled Services Day Training Agency	$0	$12.1M
Carepoint Emergency Medicine Kansas LLC	KS	Emergency Medicine Physician	$0	$11.8M
Hunter Health Clinic Inc	KS	Federally Qualified Health Center (FQHC)	$0	$10.4M
Ascension Via Christi Hospitals Wichita Inc.	KS	General Acute Care Hospital	$0	$8.9M

Dennis Moore — Billing Profile & Reimbursement Data

Sign up for Dennis Moore — Billing Profile & Reimbursement Data policy alerts

Dennis Moore — Billing Profile & Reimbursement Data

Sign up for Dennis Moore — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References